Bruker Corporation (BRKR)
| Market Cap | 8.91B +76.8% |
| Revenue (ttm) | 3.50B +1.7% |
| Net Income | -106.90M |
| EPS | -0.70 |
| Shares Out | 152.36M |
| PE Ratio | n/a |
| Forward PE | 25.81 |
| Dividend | $0.20 (0.34%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | 1,334,168 |
| Open | 59.32 |
| Previous Close | 59.41 |
| Day's Range | 58.26 - 59.79 |
| 52-Week Range | 28.95 - 65.30 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 58.75 (+0.43%) |
| Earnings Date | Aug 4, 2026 |
About BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BRKR stock is "Buy." The 12-month stock price target is $58.75, which is an increase of 0.43% from the latest price.
News
Bruker, Luvata enter strategic collaboration
Bruker (BRKR) Energy & Supercon Technologies, a segment of Bruker, and Luvata Materials & Solutions, a Business Unit of Luvata Group, announced a strategic collaboration to support the growing demand…
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luva...
Bruker announces strategic collaboration with Atinary Technologies
Bruker (BRKR) Corporation announced an expanded strategic collaboration with Atinary Technologies. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory ...
Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technol...
Bruker announces majority investment in MIMETAS B.V.
Bruker (BRKR) announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment ...
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced...
Bruker price target raised to $50 from $45 at Stifel
Stifel raised the firm’s price target on Bruker (BRKR) to $50 from $45 and keeps a Hold rating on the shares.
Bruker price target lowered to $53 from $60 at Citi
Citi lowered the firm’s price target on Bruker (BRKR) to $53 from $60 and keeps a Neutral rating on the shares.
Bruker Earnings Call Transcript: Q2 2026
Q2 2026 saw a return to organic revenue growth, significant margin and EPS expansion, and robust order growth in deep tech and biopharma. FY 2026 guidance remains unchanged, with strong Q4 performance expected, driven by semiconductor and energy research demand.
Bruker Earnings release: Q2 2026
Bruker released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bruker Slides: Q2 2026
Bruker has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bruker Quarterly report: Q2 2026
Bruker has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bruker reports Q2 EPS 49c, consensus 38c
Reports Q2 revenue $838.5M, consensus $853.57M. Frank Laukien, Bruker’s (BRKR) President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments...
Bruker sees FY26 revenue $3.54B-$3.57B, consensus $3.59B
Bruker (BRKR) now expects FY26: Organic revenue growth of 1% to 2%, M&A revenue growth of approximately 1.5%, CER revenue growth of 2.5% to 3.5%, and Foreign currency translation revenue…
Bruker Reports Second Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker's Pres...
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 20...
Bruker price target raised to $60 from $45 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $60 from $45 and keeps a Hold rating on the shares. The firm adjusted targets in the tools space…
Bruker announces acquisition of DISQVER platform from Noscendo
Bruker (BRKR) Corporation announced the acquisition of the DISQVER clinical metagenomics platform from Noscendo GmbH. DISQVER enables metagenomic next-generation sequencing analysis of microbes direct...
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
BREMEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables m...
Bruker price target raised to $60 from $44 at Citi
Citi raised the firm’s price target on Bruker (BRKR) to $60 from $44 and keeps a Neutral rating on the shares.
Bruker price target raised to $70 from $50 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Bruker (BRKR) to $70 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts…
Bruker price target raised to $60 from $53 at Barclays
Barclays raised the firm’s price target on Bruker (BRKR) to $60 from $53 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
